Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Carcinoma, Hepatocellular 2Sarcoma 1Endometrial Adenocarcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Adenocarcinoma Of Esophagus 1Acrocephalosyndactylia 1

Interventions

Bevacizumab 233Fluorouracil 219Oxaliplatin 215Irinotecan 215Leucovorin 198Capecitabine 153Cetuximab 145Panitumumab 70Folfox protocol 51regorafenib 43Radiotherapy 38pembrolizumab 37IFL protocol 36HMPL-013 36trifluridine tipiracil drug combination 32Nivolumab 32Drug Therapy 26Neoadjuvant Therapy 24Trifluridine 18Celecoxib 18tislelizumab 17XELOX 17sintilimab 16Trastuzumab 16durvalumab 15atezolizumab 15aflibercept 15Chemotherapy, Adjuvant 15apatinib 14Gemcitabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colorectal Neoplasms × brivanib × Clear all
NCT01367275 2020-09-03

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

M.D. Anderson Cancer Center

Phase 2 Terminated
8 enrolled 5 charts
Gastrointestinal

Acrocephalosyndactylia, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡